Amelioration of collagen-induced arthritis by thrombin inhibition.
The deleterious role of fibrin deposition in arthritic joints prompted us to explore the effect of the thrombin inhibition on the course of collagen-induced arthritis (CIA) in the mouse. CIA was induced in male DBA/1J mice using native chicken type II collagen. The thrombin inhibitor polyethyleneglycol-hirudin (PEG-hirudin) was given for 16 days, starting 20 days after the first immunization (preventive treatment) or at the onset of clinical signs of arthritis (curative treatment). All the mice treated with PEG-hirudin had a significantly prolonged clotting time compared with control mice. PEG-hirudin, administered in a preventive way, led to significantly reduced incidence and severity of CIA during most of the treatment period, as assessed by clinical scoring. Accordingly, histological features showed a significant diminution of synovial hyperplasia in PEG-hirudin-treated mice compared with untreated mice. There was also a significant downmodulation of the synovial proinflammatory IL-1beta and IL-12p35 cytokine mRNAs in treated mice. Intra-articular fibrin, evaluated by immunohistochemistry, was significantly reduced in treated mice compared with control mice and correlated with both clinical and histological scorings. Most importantly, once arthritis was established, PEG-hirudin also showed a curative effect. In conclusion, PEG-hirudin can both prevent the onset of CIA in a dose-dependent manner and ameliorate established arthritis, suggesting that thrombin inhibition may offer a new therapeutic approach in arthritis.
Laboratoire de Rhumatologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
I
I
Marty
V
V
Péclat
G
G
Kirdaite
R
R
Salvi
A
A
So
N
N
Busso
D000818:Animals; D000991:Antithrombins / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003094:Collagen / Q000276:immunology; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D005337:Fibrin / Q000378:metabolism; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D007074:Immunoglobulin G / Q000096:biosynthesis; D007719:Knee Joint / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D044463:Receptor, PAR-1; D018179:Receptors, Thrombin / Q000096:biosynthesis / Q000235:genetics; D013583:Synovial Membrane / Q000187:drug effects / Q000473:pathology; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013927:Thrombosis / Q000378:metabolism / Q000473:pathology; D014158:Transcription, Genetic / Q000187:drug effects; D014914:Whole Blood Coagulation Time
D000991:Antithrombins; D016207:Cytokines; D006629:Hirudins; D007074:Immunoglobulin G; D044463:Receptor, PAR-1; D018179:Receptors, Thrombin; C104614:polyethyleneglycol-hirudin; D005337:Fibrin; D003094:Collagen; D013917:Thrombin